INmune Bio (NASDAQ: INMB) is a diversified clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to combat disease. An article further discussing the company reads, “Drug candidates INKmune and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product … Continue reading “NetworkNewsBreaks – Why INmune Bio Inc. (NASDAQ: INMB) Is ‘One to Watch’”
INmune Bio is at the vanguard of reprogramming the innate immune system for the treatment of disease The company’s focus is on modulating components of the innate immune system to treat cancer and Alzheimer’s disease INmune Bio’s drug candidates include INKmune, INB03 and XPro1595 INmune Bio Inc. (NASDAQ: INMB) is a diversified, clinical-stage biotechnology company … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Focusing on New Immunotherapies that Reprogram Immune Systems”
About INmune Bio Inc. INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. … Continue reading “NetworkNewsAudio – INmune Bio Inc. (NASDAQ: INMB) Interview”
INmune Bio (NASDAQ: INMB) is a clinical-stage biotechnology company developing therapies targeting the innate immune system in cancer. INmune Bio is developing two products platforms that reengineer the patient’s innate immune system’s response to their cancer, INKmune and INB03. INKmune is a Natural Killer (NK) cell therapeutic that primes the patient’s NK cells to attack … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Starts Presentation at 9th Annual LD Micro Invitational”
INmune Bio Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, on Tuesday announced that its director of neuroscience, CJ Barnum, Ph.D., will be giving a scientific talk and presenting a poster on Alzheimer’s drug candidate XPro1595 at the TNF Conference on June 4, … Continue reading “NetworkNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) to Showcase Alzheimer’s Drug Candidate XPro1595 at TNF Conference”
A presentation by INMB co-founder and CFO David Moss is slated for June 5 at 10:20 a.m., with one-on-one meetings also available The company’s active drug candidates are INKmune and INB03, which may be used to treat cancer, and XPro1595, which targets neuroinflammation as a cause of Alzheimer’s disease INMB received a $1 million grant … Continue reading “INmune Bio Inc. (NASDAQ: INMB) to Offer Updates on Novel Immunotherapies During LD Micro Invitational”
INmune Bio is a diversified, clinical stage immunology company developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease Drug candidates INKmune and INB03 may be used to treat cancer; XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease The company was awarded a $1 million “Part the Cloud” grant … Continue reading “INmune Bio Inc. (NASDAQ: INMB) Developing Novel Immunotherapies Targeting Alzheimer’s Disease, Cancer”
INmune Bio’s IPO closed February 1, 2019, with NASDAQ Capital Markets listing on February 4, 2019 Public clinical-stage immunology company with programs in oncology and neurodegenerative disease INmune Bio targets large markets with unsolved problems such as resistance to checkpoint inhibitor therapy, a fast-growing oncology market segment; MRD, the cause of cancer relapse; and neuroinflammation … Continue reading “INmune Bio Inc. (NASDAQ: INMB) is “One to Watch””
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that its co-founder and CFO David Moss will present at the Ninth Annual LD Micro Invitational. The event will be held on June 4 to 5, 2019 at the Luxe Sunset Boulevard … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) to Present at Ninth Annual LD Micro Invitational on June 5”
INmune Bio (NASDAQ: INMB) this morning announced a common stock purchase agreement with Chicago-based institutional investor Lincoln Park Capital Fund, LLC (“LPC”) for up to $20 million, including an initial investment of $300,000. The investment amount is subject to the terms of the agreements with Lincoln Park and is in addition to LPC’s investment during … Continue reading “NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Enters Common Stock Purchase Agreement with Lincoln Park Capital”
